- Cancer Immunotherapy involves antibodies to inhibit immune checkpoint molecules. Fighting cancer with immunotherapy has revolutionized treatment for some patients and therapies targeting the immune checkpoint molecules such as CTLA-4 and PD-1 in melanoma, renal cancer, Hodgkin’s diseases and lung cancer.
- Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth.
- T cells are a type of white blood cells that are a part of the immune system. Activation of cytotoxic T cells by antigens enables them to kill unhealthy or foreign cells. It binds MHCII molecules and modulates T-cell function than either CTLA-4 or PD-1.
LAG-3-Next Generation Immunotherapy Market
LAG-3-Next Generation Immunotherapy Market is expected to generate USD 3,421 Million by 2035.
LAG-3-Next Generation Immunotherapy Market Drivers-
- The launch of potential upcoming therapies in the LAG-3 target during the forecast period (2022–2035).
- Addition of personalized drug therapies with combinational therapies to enhance the efficacy
- Increasing funding for R&D expense
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics
LAG-3-Next Generation Immunotherapy Pipeline
- MGD013: MacroGenics/Zai Lab
- MBG453: Novartis
- Relatlimab: Bristol-Myers Squibb/Ono Pharmaceuticals
- Eftilagimod Alpha (IMP321): Immutep
- LAG525: Novartis
- MK-4280: Merck
- REGN3767: Regeneron
- FS118: F-star Therapeutics
- XmAb22841: Xencor
- INCAGN2385: Incyte Biosciences/Agenus
- RO7247669: Roche
- TSR-033: GlaxoSmithKline
- IBI110: Innovent Biologics (Suzhou) Co. Ltd.
And many others
Scope of the report
• The report covers the descriptive overview of LAG-3-Next Generation Immunotherapy, explaining its pathophysiology, and current trends in the research.
• Additionally, an all-inclusive account of emerging therapies for LAG-3-Next Generation Immunotherapy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of LAG-3-Next Generation Immunotherapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the LAG-3-Next Generation Immunotherapy market.
1. Key Insights
2. Executive Summary
3. Competitive Intensity of LAG-3-Next Generation Immunotherapy
4. Market Competition of LAG-3-Next Generation Immunotherapy
5. Technological innovations in LAG-3-Next Generation Immunotherapy
6. Multivariate analysis of the key players in LAG-3-Next Generation Immunotherapy
7. LAG-3-Next Generation Immunotherapy Market Overview at a Glance
7.1. Market Share (%) Distribution of Next-Generation Immunotherapy in 2035
8. Pipeline Therapeutics Analysis (Active Products)
9. Overview: Next Generation Immunotherapy
9.1. Immune Checkpoint Inhibitors
9.2. LAG-3
10. Future Prospects and Challenges in LAG-3-Next Generation Immunotherapy
10.1. Current Clinical Challenges in Immunotherapies
10.2. Future direction of improving response rates of Immunotherapy
11. SWOT Analysis
12. Epidemiology and Forecasting Assumptions
13. Emerging Drugs
13.1. Target indications of LAG-3
13.2. MGD013: MacroGenics/Zai Lab
13.2.1. Drug Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Product Profile
13.3. MBG453: Novartis
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Product Profile
13.4. Relatlimab: Bristol-Myers Squibb/Ono Pharmaceuticals
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Product Profile
13.5. Eftilagimod Alpha (IMP321): Immutep
13.5.1. Drug Description
13.5.2. Clinical Development
13.5.3. Product Profile
13.6. LAG525: Novartis
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Product Profile
13.7. MK-4280: Merck
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Product Profile
13.8. REGN3767: Regeneron
13.8.1. Product Description
13.8.2. Other Developmental Activities
13.8.3. Clinical Development
13.8.4. Product Profile
13.9. FS118: F-star Therapeutics
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Product Profile
13.10. XmAb22841: Xencor
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Product Profile
13.11. INCAGN2385: Incyte Biosciences/Agenus
13.11.1. Product Description
13.11.2. Other Developmental Activities
13.11.3. Clinical Development
13.11.4. Product Profile
13.12. RO7247669: Roche
13.12.1. Product Description
13.12.2. Other Developmental Activities
13.12.3. Clinical Development
13.12.4. Product Profile
13.13. TSR-033: GlaxoSmithKline
13.13.1. Product Description
13.13.2. Other Developmental Activities
13.13.3. Clinical Development
13.13.4. Product Profile
13.14. IBI110: Innovent Biologics (Suzhou) Co. Ltd.
13.14.1. Product Description
13.14.2. Other Developmental Activities
13.14.3. Clinical Development
13.14.4. Product Profile
14. Assessment by Indication
15. Assessment by Route of Administration
16. Assessment by Stage and Indication
17. Assessment by stage and Route of Administration
18. LAG-3-7 Major Market Analysis
18.1. Market Outlook in the 7MM
18.1.1. Total Market size of LAG-3 in 7MM
18.1.2. Market Size of LAG-3 by indication in 7MM
19. Market Drivers
20. Market Barriers
21. Appendix
21.1. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/